Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating arbaclofen placarbil as adjunctive therapy for gastroesophageal reflux disease completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Arbaclofen placarbil (XP19986) (arbaclofen placarbil)

Snippet

Sponsor: XenoPort, Inc. | Conditions: Gastroesophageal Reflux Disease | Phase 2 | Status: COMPLETED